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Abstract: 
Background/Objectives 
Retinopathy of prematurity (ROP) is a potentially blinding disorder affecting 
premature infants. Our Eye Unit supports 2 neonatal intensive care units (NICUs), 
one provides neonatal surgical and medical facilities and the other is exclusively 
medical. Our objectives were to (1) to identify the annual rate of ROP treatments 
during the period 2009-2015 and (2) to estimate the incidence of ROP treatment in 
babies born very prematurely (<27 weeks).   
Subjects/Methods 
Records for all infants treated for ROP by our unit during the period 2009-2015 were 
reviewed. We calculated numbers treated in each year. Records of babies born under 
27 weeks of gestation and cared for in the non-surgical NICU were also reviewed. 
Their requirement for laser treatments for ROP was calculated by week of gestation at 
birth. 
Results 
In the 2 NICUs combined, 95 infants were treated for ROP between 2009 and 2015. 
The numbers treated increased from 9/158 (5.7%) of babies screened in 2009 to 
22/159 (13.8%) in 2015 (ptrend 0.004). The rate of laser treatment for ROP increased as 
gestation at birth decreased: from 12/100 (12%) of babies born at 26 weeks to 17/29 
(59%) of babies born at 23 weeks (ptrend =0.001). 
Conclusion 
The number of laser treatments for ROP carried out by this unit has increased steadily 
between 2009 and 2015 and may in part be due to the increased need for ROP 
treatment in extremely preterm babies, whose survival has increased in the same 
period. This data may aid planning for ROP services. 
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Introduction: 
Retinopathy of prematurity (ROP) is a potentially blinding disorder affecting 
premature infants. Risk factors include a low gestational age and a low birth weight1. 
ROP is a major cause of preventable blindness in children worldwide2. The proportion 
of blind children affected by ROP has been reported as 37.4% in Former Soviet 
Economies and 23.9% in Latin American countries, in contrast with 10% in 
established market economies such as the UK and nil or extremely rare in sub-
Saharan Africa1. The reasons for these differences are thought to include variation in 
levels of training in neonatal care and the ability to monitor oxygen saturations in 
babies having supplemental oxygen and the availability of ophthalmic support for 
screening and treatment. 
 
Guidelines exist for screening to identify sight-threatening stages of ROP and to 
instigate timely treatment. Screening and treatment for ROP in the UK follows the 
guidelines set jointly by The Royal College of Ophthalmologists and the Royal 
College of Paediatrics and Child Health3. These use the nomenclature and 
descriptions (location in retinal zones 1-3; severity in stages 1-5 and plus or pre-plus 
to describe increases in retinal vessel calibre and tortuosity) of the International 
Committee for the Classification of ROP4. The current criteria for treatment are based 
on the Early Treatment of Retinopathy of Prematurity Study (ETROP)5. The features 
of ROP requiring treatment are collectively known as “Type 1 ROP” which includes 
any stage ROP in zone 1 with Plus; Zone 1 stage 3 with or without plus; zone 2 stage 
2 or 3 ROP with plus. Treatment may also be given for “Type 2 ROP” if there is 
clinical concern, otherwise this can be kept under review until progression to type 1 
ROP or regression takes place. 
 
 4 
 
Screening in the UK is currently recommended for all babies born at less than 32 
weeks gestation or weighing less than 1501 grams, starting at 4-5 weeks after birth or 
30 weeks gestation (whichever is the later) and should continue until the retina is fully 
vascularised, or treatment is required. A recent national prospective surveillance study 
in the UK reported the incidence of ROP requiring treatment to be 4% in infants with 
birth weight <1500g6, which is greater than previous estimates of 1.5-2%7,8. This 
study reported the majority of primary treatments for ROP were by diode laser 
photoablation of the avascular retina in 90.5% of babies and intravitreal injection of 
an anti-VEGF (currently not licensed) in 8%6.  
 
In our Eye Hospital unit we treat babies with ROP cared for in either of two local 
level 3 neonatal intensive care units (NICUs) and some babies from other NICUs as 
requested. One of our NICUs offers regional surgical and medical facilities for 
neonates, whilst the other is exclusively medical and cares for a higher proportion of 
the extreme premature infants.  
 
We had noticed an increase in the numbers of laser treatments being performed over 
the last few years and aimed to review this to inform future capacity planning. 
Additionally, as international studies have reported increased incidence of treatment-
requiring ROP in very prematurely-born babies as compared with babies born at 
higher gestations9,10,11,12, we aimed to determine whether this was the case for our 
UK-born neonates.  
 
The aims of this study were therefore twofold: firstly, describe yearly ROP treatments 
during the 7-year study period (2009 to 2015) and secondly to estimate the rates of 
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ROP requiring treatment in infants born very preterm (<27 weeks), by weekly 
category of gestational age. 
 
Patients and methods: 
 
First aim: laser treatments carried out per year by our unit 
For the first aim we retrospectively reviewed the clinical data of all the infants that 
were treated for ROP by the Vitreoretinal (VR) team at Bristol Eye Hospital between 
1 January 2009 to 31 December 2015. Babies screened for ROP in Bristol include 
Bristol-booked infants and babies transferred to Bristol for tertiary care. Of note, the 
referral pathways did not change over the time period studied. The Western Network 
and Peninsula Network (lead centre Plymouth) combined in January 2013 to form the 
South West Neonatal Network but this did not change the referral pathways for the 
tertiary units in the Network so Bristol did not receive referrals from a wider area at 
any time during the study. 
 
 
For all babies we used the recommended criteria for screening (birth weight <1500g 
and/or <32 weeks gestation) and the first examination was at 4-5 weeks after birth or 
30 weeks gestation, whichever was the later. Examinations were carried out weekly. 
Treatment decisions were based on the 2008 RCOphthal ROP Guidelines3. Initial 
treatment for all subjects consisted of transpupillary indirect ophthalmoscope diode 
laser therapy of laser burns to the entire avascular retina. Review was undertaken 
within 5-7 days, then weekly after treatment and the decision for further treatment 
(with either an intravitreal anti VEGF agent, further laser or vitrectomy) was taken 2-
3 weeks later if regression was not evident. 
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Infants that had been treated for ROP during the study period were retrospectively 
identified from a laser book held at the Eye Hospital and cross-referenced against lists 
held by the individual neonatal units identifying the individuals that were treated. 
Clinical data was taken from the neonatal electronic patient record database Badger 
Net.  
 
Second aim: rates of ROP needing treatment by gestational age at birth 
For the second aim, we reviewed the notes and database records of all babies under 27 
weeks cared for in the exclusively medical NICU. Care of babies under 27 weeks in 
the Western neonatal network is centralised to NICUs in our area, the majority in the 
exclusively medical NICU. In order to estimate the survival rates and the need for 
laser treatment in extremely premature infants, we used as denominator all infants 
who were born or transferred within 48 hours of birth to the exclusively medical 
NICU. For those who were transferred out of our area before their ROP screening was 
completed we checked the national or regional neonatal database for details of any 
laser treatments carried out elsewhere. 
 
Therefore the groups of babies used to answer each question are not the same, 
although there is overlap between them. Statistical significance was assessed with 
extended Mantel-Haenszel chi square for linear trend. 
 
Results: 
 
Study Aim 1: Laser treatments carried out each year between 2009 and 2015 
 
 7 
 
During the 7-year study period, a total of 95 infants were treated for ROP, by the local 
vitreoretinal team (table 1). Laser treatments were carried out under sedation and 
muscle relaxant, with intubation to support their ventilation. Each NICU had a 
dedicated room for the purpose and provided full nursing and neonatology support. 
 
Total infants 95  
Gender 
Male 
Female 
 
48 (50.5%) 
47 (49.5%) 
Maternal steroids  
 
87%  
Birth weight (mean±SD) 699.9 ± 160.7g  
 
Gestation (mean ± SD) 24 weeks ± 1.3 weeks 
 
Age at which treatment was undertaken 
(mean±SD) 
90.6 ± 45.7 days  
 
Table 1: Details of the 95 infants treated for ROP by the VR consultants at Bristol 
Eye Hospital between 2009-2015.  
  
Over the time period studied (2009-2015) 8.2% of the infants who were examined, 
required treatment for ROP. There was a year-on-year increase in the absolute number 
treated with significantly more treated in 2015 compared to 2009 (Table 2).  In the 
majority of cases (82 of 95, 86%) treatment consisted of one course of laser treatment 
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alone. Additional treatment following the first course of laser was required in the 
remainder (13 of 95, 14%). This consisted of two courses of laser in 5 of 95 (5.3%), 
laser followed by an intravitreal injection of anti vascular endothelial growth factor 
(VEGF) in 7 of 95 (7.4%) and laser followed by vitrectomy in 1 of 95 (1.1%), in this 
case the infant was referred to a different centre for the vitrectomy due to aggressive 
ROP failing to regress following the initial laser treatment.  
 
Of these 95 babies, approximately two thirds were not later resident in Bristol, but 
were transferred to other units near their homes. 
 
 
Year Numbers of 
babies treated 
Numbers of 
babies 
examined in 
the two 
NICU units 
combined 
Percentage of 
examined 
babies treated 
2009 9 158 5.7% 
2010 9 169 5.3% 
2011 12 177 6.8% 
2012 16 162 9.3% 
2013 11 162 6.8% 
2014 16 165 9.7% 
2015 22 159 13.8% 
Totals 95 1152 8.2% 
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Table 2: ROP treated infants as a percentage of those screened each year. A 
significantly greater percentage of infants were treated each year following a linear 
trend. Extended MH Chi Sq = 8.24, df=1, p=0.004. 
 
Study Aim 2: Incidence of ROP treatment by gestational age 
Over the time period studied (2009-2015) 333 infants <27 weeks were cared for at the 
exclusively medical NICU. Of these 269 (81%) survived to complete ROP screening 
(table 3). Figure 1 shows the number of babies <27 weeks gestation cared for at the 
exclusively medical NICU and the number surviving to complete ROP screening 
increased from 2009 to 2015. Their survival improved from 69% in 2009 to 90% in 
2015. 
 
 
Figure 1: The number of <27 weeks gestation babies cared for and survived to 
complete ROP screening by year of birth.  
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Survival to complete ROP screening improved with increasing gestation; 69% of 23 
week gestation and 88% of 26 week gestation infants survived (table 3). ROP 
treatment was required for 69 of 269 (26%) of extremely premature babies that 
survived to complete ROP screening. Of these 56 (81%) were treated in Bristol (and 
are included in the first study aim) and 13 (19%) were treated at their base unit. The 
incidence of ROP treatment increased in proportion with the degree of prematurity at 
birth: extended MH chi sq for linear trend =28.57; df=1; p <0.001. As shown in 
Figure 2, 17/29 (59%) of those born at 23 weeks gestation required treatment 
compared to 12/100 (12%) of those born at 26 weeks gestation (Figure 2).  
Table 3. Outcome for those <27 weeks cared for at Southmead 
Gestation 
(weeks+days) 
23+0 to 
23+6 
24+0 to 
24+6 
25+0 to 
25+6 
26+0 to 
26+6 
23+0 to 
26+6 
Number 42 74 104 113 333 
Survived to 
complete 
ROP 
screening 
(%) 
29 
(69%) 
58 
(78%) 
82 
(79%) 
100 
(88%) 
269 
(81%) 
Survivors 
treated for  
ROP (%)  
17 
(59%) 
22 
(38%) 
18 
(22%) 
12 
(12%) 
69 
(26%) 
Survival 
without  
ROP (%) 
12 
(29%) 
36 
(49%) 
64 
(62%) 
88 
(78%) 
200 
(60%) 
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Died + ROP 
treatment (%) 
30 
(71%) 
38 
(51%) 
40 
(38%) 
25 
(22%) 
133 
(40%) 
Table 3: Numbers care for and percentage survival to complete ROP screening for 
each week of gestation. 
 
 
Figure 2: Incidence of ROP treatment by gestational age at birth. 
 
Discussion: 
We aimed to answer two questions: firstly, was our unit carrying out increasing 
numbers of laser treatments for ROP over the last few years and secondly, in a cohort 
of extremely premature infants, did the rates of ROP needing treatment vary by week 
of gestational age at birth. We found that the absolute numbers of laser treatments 
carried out had increased, with no increase in the overall numbers of babies examined 
each year, suggesting the babies in our local units were increasingly higher-risk (for 
ROP) as the study period progressed. We also observed that in a cohort of extremely 
premature (<27 weeks at birth) infants, not only were they increasingly more likely to 
survive as the study period progressed, but also the rate of ROP requiring treatment 
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varied inversely with their gestational age at birth.  Thus whilst 12% of babies born at 
26 weeks and survived needed laser for ROP, this was nearly fivefold higher for 
babies born at 23 weeks and survived (table 3). These data suggest that the increase in 
ROP treatments we have carried out during the study period is in part be due to the 
increased survival of the more extreme premature infants. A recent population-based 
study showed the survival to discharge of extreme preterms in England between 
2008-2014 was 36% for 23 weeks gestation, 59% for 24 weeks, 74% for 25 weeks 
and 83% for 26 weeks13. These survival rates are lower than those we observed in this 
study especially for the lower gestations (69% for 23 weeks gestation and 78% for 24 
weeks). Thus a small improvement in survival of the more extremely premature 
babies especially those at 23 and 24 weeks gestation will have a greater impact on the 
numbers requiring ROP treatment and therefore the ophthalmology service. Since 
2008, in the UK as a whole, all care for <27 weeks gestation infants has been 
centralised to tertiary neonatal units such as the two in our city.  This centralisation of 
services also increases the demands on the reduced numbers of Eye units carrying out 
ROP treatments and is a likely additional reason for the increase in ROP treatments 
we have observed. 
 
Our study is not a population-based study and therefore cannot be used to estimate 
incidence of ROP treatment of those eligible for screening (<1500g and/or <32 weeks 
gestation). The babies examined in the two NICUs include Bristol-booked infants and 
those born <27 weeks from the wider regional neonatal network, but excludes 
prematurely-born local babies cared for in nearby level 2 centres. Previous studies 
have reported incidence of ROP treatment is increasing14 and the recent national 
surveillance study found that more babies were treated for ROP in 2014 than were 
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reported in a previous national study15. In our study all babies were treated by diode 
laser as a primary treatment and 13.7% (13/95) required further treatment. This is 
similar to the national picture6. The use of other forms of treatment such as anti 
VEGF intravitreal injections remains off licence in the UK, and this is an area where 
further research is required, particularly in identifying the safety profile of these 
medications systemically in premature infants. In our study, an anti VEGF intravitreal 
injection was used as a second-line agent in 7 of the 13 cases where initial treatment 
had failed to result in resolution of the ROP. In the recent national audit 8% of babies 
received anti-VEGF as firstline treatment6. Other reports have suggested that anti 
VEGF intravitreal injections, may be of value in cases where there is poor visibility of 
the retina, which would make laser treatment difficult, or in cases where laser 
treatment has failed to result in regression of ROP16. 
 
A limitation of our study is that we have considered just one geographic area and the 
results may not be generalizable to other areas. The recording of ROP laser treatments 
in the laser book and/or the neonatal database may have been inaccurate and we could 
not cross-check data sources for babies treated outside our unit. We did not record 
stage of ROP triggering the decision to treat, so the threshold for treatment may have 
varied over the study period and there is also well-recognised variability between 
ophthalmologists for example regarding presence or absence of Plus disease17. 
However the same team were involved in screening and treatment throughout the 
period and national guidelines did not change.  A strength of this study is that we have 
defined a cohort of extreme preterms and obtained ROP-treatment outcome for all of 
them. This study therefore can estimate the incidence of ROP treatment in this 
defined population and has identified a greatly increased risk of needing ROP 
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treatment for babies born at 23 or 24 weeks, compared to babies born when more 
mature. There are no reports of ROP treatment rate by gestation from other UK 
centres but similar observations to ours have been made in other countries9,10,11,12.   
 
In conclusion, the recent increase in the incidence of ROP requiring treatment, which 
we have seen locally over our 7-year study period, appears to be at least in part due to 
the increased survival of premature infants. With on-going advances in neonatal 
intensive care facilities, particularly in developed countries, leading to the greater 
survival of extremely premature infants, it is likely that the incidence of ROP and 
ROP requiring treatment will continue to rise in future. With increasing centralisation 
of specialised services, the data we present may help capacity planning and service 
design for Eye Units involved with care of babies with ROP. The data will also help 
neonatologists and ophthalmologists when counselling the parents of babies born 
extremely preterm, about the likelihood of ROP developing which requires treatment. 
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